Rheumatoid arthritis: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• JAK 9
• TNF 9
• STAT3 0
• IL-6 2
• PI3K 0
• NLRP3 0
• CD19 17
• MAPK 0
• HIF-1 0
• NRF2 0
• mTOR 0
• IL-17 0
• AKT 0
• STING 0
• RANKL 0
• PPAR 0
• COX-2 0
• IL-1 0
• TLR4 0
• CD20 2
• TP53 0
• ERK 0
• PD-1 1
• SIRT1 0
• BCMA 7
• GLP-1 0
• MMP-9 0
• CTLA-4 1
• CTNNB1 0
• GPX4 0
• JNK 0
• SGLT2 1
• VEGF 1
• CD40 0
• HMGB1 0
• AMPK 0
• APOE 0
• AQP4 0
• CCR5 0
• FGFR 0
• IL-15 1
• METTL3 0
• PKM2 0
• TYK2 0
• CD38 1
• CGRP 0
• CXCR4 0
• IDO1 0
• PD-L1 0
• TIGIT 0
• BTK 0
• CD47 0
• EGFR 0
• HDAC 0
• IDH 0
• IL-23 0
• IL-4 0
• KEAP1 0
• MEK 0
• MYC 0

2478 intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  HARPNET – Harnessing Resolution Pharmacology for Next-Generation Therapeutics

  Queen Mary University of London· London, Egyesült Királyság· EU contribution 4 793 228 EUR· until 2030. szept.· 8 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  BSSL TARGETING THERAPY TOWARDS NON-IMMUNOSUPPRESSIVE RA TREATMENT (SOL-116 - BEYOND)

  Lipum Ab· Umea, Svédország· EU contribution 7 995 375 EUR· until 2029. jún.· 3 countries

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  PRECISION-RA: Precision Immunotherapy for Rheumatoid Arthritis

  University of Bristol· Bristol, Egyesült Királyság· EU contribution 150 000 EUR· until 2027. nov.

• European Commission (Horizon Europe) · HORIZON-ERC

  Advancing NANOmedicines to rewire tumoral MYeloid cells for next-generation cancer immunotherapies (My-NANO)

  Universiteit Gent· Gent, Belgium· EU contribution 2 499 750 EUR· until 2031. ápr.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Development of Armored targeted CAR-T cells for immune reset of T cell-mediated autoimmune diseases (iCARUS)

  Weizmann Institute of Science· Rehovot, Izrael· EU contribution 150 000 EUR· until 2027. szept.

  The disease is named only in the funder's project summary, not in the title.

5 of 35 running projects, newest first. Listed amounts together: 169,1 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Leállították

  Evaluation of a Connected Interface to Improve the Quality of Life and the Disability of Patient With Rheumatic Diseases

  NCT05417477· University Hospital, Montpellier· Frissítve: 2026. nov. 10.

  “Problems encountered with the device used in the study”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  Microbiota Analysis to Predict Outcomes of Rheumatoid Arthritis Patients Treated With JAK-inhibitor

  NCT04530305· University Hospital, Montpellier· Frissítve: 2026. okt. 26.

  “Evolution of treatment sequencing for JAK inhibitors”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Cannabichromene Safety in Rheumatoid Arthritis

  NCT07087938· Crystal Lederhos Smith· Frissítve: 2026. szept. 23.

  “Study did not begin recruiting participants due to insufficient preclinical evidence resulting in FDA clinical hold.”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease

  NCT04031469· ProgenaBiome· Frissítve: 2026. szept. 21.

  “Administrative”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  CD40L Antagonism in Rheumatoid Arthritis (RA)

  NCT05306353· National Institute of Allergy and Infectious Diseases (NIAID)· Frissítve: 2026. júl. 20.

  “The study is being closed early due to insufficient participant enrollment across study sites.”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  An Efficacy and Safety Study of Subcutaneous Anakinra in Chinese Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset Still's Disease (AOSD)

  NCT07706868· Swedish Orphan Biovitrum· Frissítve: 2026. júl. 16.

  “Business decision”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Multidisciplinary Approach for Treat To Target In Rheumatoid Arthritis

  NCT02720874· Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center· Frissítve: 2026. júl. 2.

  “Terminated due to several programmatic delays such as personnel transitions and departures, challenges to replace them as specified in the protocol, and delays due to COVID-19 pandemic-related institutional closures and clinical research pauses.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  A Study of LY3541860 in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis

  NCT06859294· Eli Lilly and Company· Frissítve: 2026. jún. 17.

  “The interim analysis data failed to demonstrate the intended treatment effect.”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  An Open-label Study of GC012F in Rheumatoid Arthritis.

  NCT07315503· Institute of Hematology & Blood Diseases Hospital, China· Frissítve: 2026. jún. 10.

  “Due to the sponsor's adjustment of the research and development strategy for this clinical trial, this study was prematurely terminated, and no subjects were recruited for this study”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

  NCT05000216· National Institute of Allergy and Infectious Diseases (NIAID)· Frissítve: 2026. jún. 10.

  “The study was closed due to continued enrollment hurdles.”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

  NCT03816345· National Cancer Institute (NCI)· Forrás

• A Study of AZD0120 in Autoimmune Diseases

  NCT07295847· AstraZeneca· Forrás

• Platform Study of Targeted Therapies for Adults With Moderately to Severely Active Rheumatoid Arthritis

  NCT07904754· AbbVie· Forrás

• A Trial in Healthy Adult Participants and Adults With Autoimmune Diseases to Test How HBM7020 is Tolerated and How it Behaves in the Body

  NCT07649265· Otsuka Pharmaceutical Development & Commercialization, Inc.· Forrás

• Overactive Bladder Symptoms and Urinary Incontinence In Women With Rheumatoid Arthritis

  NCT07916623· Ege University· Forrás

• A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004)

  NCT07363590· Merck Sharp & Dohme LLC· Forrás

• Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants

  NCT07201558· AstraZeneca· Forrás

• A Clinical Trial of MK-8690 in Participants With Rheumatoid Arthritis (MK-8690-004)

  NCT07895524· Merck Sharp & Dohme LLC· Forrás

• COVID-19 Booster and IIV Schedule in Immunocompromised Hosts

  NCT06599658· McGill University Health Centre/Research Institute of the McGill University Health Centre· Forrás

• Efficacy of JAK STAT Pathways Inhibitors in Treatment of Patients With Rheumatoid Arthritis

  NCT05788705· Adel A.Gomaa· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 43
• Organoids 3
• Mendelian Randomization Analysis 97
• CRISPR-Cas Systems 1
• Gene Expression Profiling 121
• Sequence Analysis, RNA 17
• Exome Sequencing 2
• Proteomics 52
• Metabolomics 45
• Mass Spectrometry 7
• Flow Cytometry 33
• Immunohistochemistry 18
• Liquid Biopsy 1
• Xenograft Model Antitumor Assays 2
• Positron-Emission Tomography 5
• Magnetic Resonance Imaging 58
• Machine Learning 87
• Deep Learning 9
• Cohort Studies 160
• Genome-Wide Association Study 113

• Immunoprecipitation-mass spectrometry reveals known and novel (NatC, BCS1L) antinuclear antibodies in rheumatoid arthritis.

  RMD Open, 2026. ápr.

• Prediction and Characterization of Glycated Peptides and Proteins using Hydrophilic Interaction Liquid Chromatography coupled with Mass Spectrometry (HILIC-MS).

  J Biomol Tech, 2026. márc.

• Study of GJKBW against RA based on the Chinmedomics combined LIP-MS molecular fishing technology: A new strategy for discovering the therapeutic material basis.

  J Pharm Biomed Anal, 2026. márc.

• A UHPLC-Orbitrap-MS Metabolomics Strategy Reveals Glycerophospholipid Metabolic Remodeling Is Associated with the Anti-Arthritic Effect of Glycyrrhiza Protein-Paeoniflorin Nanoparticles via PI3K/AKT/NLRP3 Axis.

  Molecules, 2026. febr.

• The rheumatoid arthritis citrullinome is enriched in antigenic complement proteins.

  Arthritis Res Ther, 2026. jan.

• Siwei Zangmu Xiang alleviates rheumatoid arthritis via regulating RAGE signaling pathway: Integration of UPLC-Q-TOF-MS, network pharmacology, and in vivo/in vitro studies.

  J Ethnopharmacol, 2025. dec.

• Haptoglobin-α1, -α2, vitamin D-binding protein and apolipoprotein C-III as predictors of etanercept drug response in rheumatoid arthritis.

  Arthritis Res Ther, 2015. márc.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.